Diabetic neuropathies

CONTINUUM Lifelong Learning in Neurology

Volumn 20, Issue 5, 2014, Pages 1226-1240

  Russell, James W ^a   Zilliox, Lindsay A ^a  

^a Department of Neurology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTONOMIC NEUROPATHY; CACHEXIA; DEMYELINATING NEUROPATHY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LUMBOSACRAL PLEXUS; MUSCLE ATROPHY; NEUROPATHIC PAIN; PATHOGENESIS; POLYNEUROPATHY; REVIEW;

EID: 84988709165     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000455884.29545.d2     Document Type: Review

References (26)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-1053.
2. Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol 2011;13(2):143-159.
3. Albers JW, Herman WH, Pop-Busui R, et al. Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007;30(10):2613-2618.
4. Smith AG, Russell JW, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006;29(6):1294-1299.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
6. Dyck PJ, Albers JW, Andersen H, et al, Toronto Expert PanelonDiabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity [published online ahead of print June 21, 2011]. Diabetes Metab Res Rev 2011. doi:10.1002/dmrr.1226.
7. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285-2293.
8. Zilliox L, Peltier AC, Wren PA, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology 2011;76(12):1099-1105.
9. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003;52(12):2867-2876.
10. Goldberg A, Russell JW, Alexander NB. Standing balance and trunk position sense in impaired glucose tolerance (IGT)-related peripheral neuropathy. J Neurol Sci 2008;270(1-2):165-171.
11. Spallone V, Ziegler D, Freeman R, et al, Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management [published online ahead of print June 22, 2011]. Diabetes Metab Res Rev 2011. doi:10.1002/dmrr.1239.
12. Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002;25(4):477-491.
13. Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain 2012;135(pt 10):3074-3088.
14. Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev 2012;6:CD006521.
15. Gibbons CH, Adler GK, Bonyhay I, Freeman R. Experimental hypoglycemia is a human model of stress-induced hyperalgesia. Pain 2012;153(11):2204-2209.
16. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010;67(4):534-541.
17. Keane JR. Third nerve palsy: analysis of 1400 personally-examined inpatients. Can J Neurol Sci 2010;37(5):662-670.
18. Said G. Focal and multifocal diabetic neuropathies. Arq Neuropsiquiatr 2007;65(4B):1272-1278.
19. Khaier A, Dawson E, Lee J. Clinical course and characteristics of acute presentation of fourth nerve paresis. J Pediatr Ophthalmol Strabismus 2012;49(6):366-369.
20. Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for symmetrical diabetic peripheral neuropathy. Cochrane Database Syst Rev 2008;(3):CD006152.
21. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012;6:CD007543.
22. Russell JW, Smith AG, Singleton JR. Impaired glucose regulation and neuropathy. In: Gilman S, ed. Neurobiology of diseases. San Diego: Elsevier, 2006:849-869.
23. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012;11(6):521-534.
24. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362(16):1477-1490.
25. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34(9):2054-2060.
26. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76(20):1758-1765.